Title |
Open-label add-on treatment trial of minocycline in fragile X syndrome
|
---|---|
Published in |
BMC Neurology, October 2010
|
DOI | 10.1186/1471-2377-10-91 |
Pubmed ID | |
Authors |
Carlo Paribello, Leeping Tao, Anthony Folino, Elizabeth Berry-Kravis, Michael Tranfaglia, Iryna M Ethell, Douglas W Ethell |
Abstract |
Fragile X syndrome (FXS) is a disorder characterized by a variety of disabilities, including cognitive deficits, attention-deficit/hyperactivity disorder, autism, and other socio-emotional problems. It is hypothesized that the absence of the fragile X mental retardation protein (FMRP) leads to higher levels of matrix metallo-proteinase-9 activity (MMP-9) in the brain. Minocycline inhibits MMP-9 activity, and alleviates behavioural and synapse abnormalities in fmr1 knockout mice, an established model for FXS. This open-label add-on pilot trial was conducted to evaluate safety and efficacy of minocycline in treating behavioural abnormalities that occur in humans with FXS. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 3 | 2% |
United States | 3 | 2% |
Australia | 1 | <1% |
Colombia | 1 | <1% |
Russia | 1 | <1% |
United Kingdom | 1 | <1% |
Unknown | 188 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 32 | 16% |
Student > Ph. D. Student | 28 | 14% |
Student > Master | 22 | 11% |
Student > Bachelor | 22 | 11% |
Student > Doctoral Student | 21 | 11% |
Other | 34 | 17% |
Unknown | 39 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 38 | 19% |
Agricultural and Biological Sciences | 32 | 16% |
Psychology | 26 | 13% |
Neuroscience | 21 | 11% |
Nursing and Health Professions | 7 | 4% |
Other | 28 | 14% |
Unknown | 46 | 23% |